Serum Institute seeks DCGI emergency use nod for rBCG tuberculosis vaccine
New Delhi: The Serum Institute has applied to the Drugs Controller General of India seeking emergency use authorisation for its recombinant BCG (rBCG) vaccine for the prevention of tuberculosis, official sources said on Sunday. The EUA application was submitted on March 22 by Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII).
Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at email@example.com Contact no. 011-43720751